Carnegie Investment Counsel’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.11M Buy
18,289
+136
+0.7% +$7.93K 0.02% 312
2025
Q4
$979K Sell
18,153
-10,008
-36% -$481K 0.02% 327
2025
Q3
$1.27M Buy
28,161
+330
+1% +$15.4K 0.02% 291
2025
Q2
$1.29M Sell
27,831
-5,429
-16% -$266K 0.03% 283
2025
Q1
$1.85M Sell
33,260
-175
-0.5% -$10.2K 0.04% 230
2024
Q4
$1.89M Buy
33,435
+1,193
+4% +$66.7K 0.05% 213
2024
Q3
$1.67M Sell
32,242
-1,297
-4% -$60.8K 0.05% 234
2024
Q2
$1.39M Sell
33,539
-18,907
-36% -$846K 0.04% 238
2024
Q1
$2.84M Sell
52,446
-25,730
-33% -$1.31M 0.09% 181
2023
Q4
$4.01M Sell
78,176
-17,309
-18% -$909K 0.14% 152
2023
Q3
$5.54M Sell
95,485
-2,364
-2% -$145K 0.21% 117
2023
Q2
$6.26M Sell
97,849
-21,956
-18% -$1.47M 0.23% 110
2023
Q1
$8.3M Buy
119,805
+10,255
+9% +$723K 0.33% 86
2022
Q4
$7.88M Buy
109,550
+187
+0.2% +$14.1K 0.34% 85
2022
Q3
$7.78M Buy
109,363
+16,477
+18% +$1.2M 0.37% 80
2022
Q2
$7.15M Sell
92,886
-4,293
-4% -$327K 0.32% 88
2022
Q1
$7.1M Sell
97,179
-381
-0.4% -$25.6K 0.26% 106
2021
Q4
$6.08M Sell
97,560
-5,703
-6% -$335K 0.2% 128
2021
Q3
$6.11M Buy
103,263
+12,777
+14% +$841K 0.23% 115
2021
Q2
$6.05M Buy
90,486
+17,241
+24% +$1.12M 0.23% 116
2021
Q1
$4.63M Buy
73,245
+11,090
+18% +$690K 0.19% 126
2020
Q4
$3.85M Sell
62,155
-1,067
-2% -$65.6K 0.17% 136
2020
Q3
$3.81M Sell
63,222
-2,647
-4% -$159K 0.19% 124
2020
Q2
$3.87M Buy
65,869
+72
+0.1% +$4.31K 0.22% 114
2020
Q1
$3.65M Sell
65,797
-2,713
-4% -$166K 0.25% 110
2019
Q4
$4.4M Buy
68,510
+1,680
+3% +$96.2K 0.25% 110
2019
Q3
$3.39M Sell
66,830
-264
-0.4% -$12.4K 0.22% 122
2019
Q2
$3.04M Sell
67,094
-17,250
-20% -$804K 0.2% 126
2019
Q1
$4.02M Buy
84,344
+3,973
+5% +$198K 0.28% 105
2018
Q4
$4.18M Sell
80,371
-65,204
-45% -$3.5M 0.39% 79
2018
Q3
$7.88M Buy
145,575
+22,461
+18% +$1.33M 0.65% 39
2018
Q2
$7.38M Buy
123,114
+20,400
+20% +$1.1M 0.56% 54
2018
Q1
$5.33M Buy
102,714
+7,686
+8% +$494K 0.45% 70
2017
Q4
$5.94M Buy
95,028
+10,744
+13% +$672K 0.53% 54
2017
Q3
$5.38M Buy
84,284
+33,110
+65% +$1.93M 0.63% 44
2017
Q2
$2.84M Buy
51,174
+10,127
+25% +$551K 0.35% 85
2017
Q1
$2.26M Sell
41,047
-177
-0.4% -$9.71K 0.28% 102
2016
Q4
$2.46M Buy
41,224
+1,834
+5% +$100K 0.33% 87
2016
Q3
$1.95M Sell
39,390
-796
-2% -$51.1K 0.28% 101
2016
Q2
$3.06M Buy
40,186
+2,899
+8% +$205K 0.43% 73
2016
Q1
$2.38M Buy
37,287
+349
+0.9% +$22K 0.36% 81
2015
Q4
$2.3M Buy
36,938
+5,850
+19% +$387K 0.4% 73
2015
Q3
$2.06M Sell
31,088
-1,036
-3% -$65.7K 0.35% 79
2015
Q2
$2.14M Sell
32,124
-833
-3% -$54.9K 0.37% 86
2015
Q1
$2.11M Sell
32,957
-2,010
-6% -$126K 0.36% 85
2014
Q4
$2.12M Buy
34,967
+75
+0.2% +$4.23K 0.4% 83
2014
Q3
$1.79M Buy
34,892
+13,817
+66% +$690K 0.36% 83
2014
Q2
$1.02M Buy
21,075
+4,480
+27% +$221K 0.23% 102
2014
Q1
$862K Hold
16,595
0.23% 103
2013
Q4
$882K Sell
16,595
-2
-0% -$102 0.24% 103
2013
Q3
$768K Sell
16,597
-4,925
-23% -$216K 0.24% 104
2013
Q2
$962K Buy
+21,522
New +$934K 0.32% 90

Other funds holding BMY

Carnegie Investment Counsel's BMY Position: Q1 2026 in Review

Carnegie Investment Counsel increased its Bristol-Myers Squibb (BMY) stake by 0.75% in Q1 2026, buying an estimated $7.93K and bringing the position to 18,289 shares worth $1.11M. The position accounts for 0.02% of the portfolio, ranked #312.

Carnegie Investment Counsel first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.3M in Q1 2023. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Carnegie Investment Counsel held 18,289 shares of Bristol-Myers Squibb worth $1.11M as of Q1 2026.
  • Carnegie Investment Counsel bought 136 Bristol-Myers Squibb shares in Q1 2026, an estimated $7.93K.
  • Bristol-Myers Squibb made up 0.02% of Carnegie Investment Counsel's portfolio in Q1 2026, its #312 holding.
  • Carnegie Investment Counsel first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Carnegie Investment Counsel's Bristol-Myers Squibb position peaked at $8.3M in Q1 2023.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Carnegie Investment Counsel's 13F filing for Q1 2026, filed 1 May 2026.